ATS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Personal Folders
Right arrow Download to citation manager
Right arrow Author home page(s):
József Furák
Imre Troján
László Agócs
Attila Csekeö
Egon Svastics
Right arrow Permission Requests
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Furák, J.
Right arrow Articles by Tiszlavicz, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Furák, J.
Right arrow Articles by Tiszlavicz, L.
Related Collections
Right arrow Lung - cancer

Ann Thorac Surg 2005;79:241-247
© 2005 The Society of Thoracic Surgeons

Original article: General thoracic

Lung Cancer and Its Operable Brain Metastasis: Survival Rate and Staging Problems

József Furák, MD, PhDa,*, Imre Troján, MDa, Tamás Szöke, MDa, László Agócs, MDb, Attila Csekeö, MD, PhDb, József Kas, MDc, Egon Svastics, MDc, József Eller, PhDd, László Tiszlavicz, MD, PhDe

a Departments of Medical Informatics, Pathology, and Surgery, University of Szeged, Szeged
b Department of Thoracic Surgery, National Korányi Institute for Pulmonology, Budapest
c Department of Surgery, Buda MÁV Hospital, Budapest, Hungary
d Department of Medical Informatics, University of Szeged, Szeged, Hungary
e Department of Pathology, University of Szeged, Szeged, Hungary

Accepted for publication June 7, 2004.

* Address reprint requests to Dr Furak, 20 Thokoly St, H-6726, Szeged, Hungary (E-mail: jfurak{at}hotmail.com).

Presented at the Fortieth Annual Meeting of The Society of Thoracic Surgeons, San Antonio, TX, Jan 26–28, 2004.

BACKGROUND: We assessed the survival rates regarding different stages of operable lung cancers causing operable brain metastasis in patients with or without cancer-related symptoms. The correlation between survival rates and the disease-free interval between lung surgery and metastasectomy was studied.

METHODS: Sixty-five patients were operated on for lung cancer and brain metastases. The disease-free interval was divided into 5 subgroups: 0–2 months, 3–5 months, 6–11 months, 12–23 months, and 24 months and beyond. The study group comprised of patients with lung cancer in the following stages: 17 patients in stage I (1 patient in stage IA, 16 patients in stage IB), 16 patients in stage II (2 patients in stage IIA, 14 patients in stage IIB), 9 patients in stage IIIA, 4 patients in stage IIIB, and 19 patients in stage IV. Forty-four patients were symptom-free for lung cancer and 21 patients manifested lung cancer related symptoms.

RESULTS: The 5-year survival rates were as follows: stage I = 22%, stage II = 20%, stage IIIA = 22%, stage IIIB = 0%, and stage IV = 23% after lung resections. There were no significant differences in the 5-year survival rates regarding the disease-free interval subgroups after brain metastasectomies (p = 0.19): disease-free interval 0–2 months = 22% and disease-free interval 24 months and beyond = 23%. The 5-year survival rate after metastasectomy was significantly greater (26% vs 5%) in patients without lung cancer related symptoms (p = 0.05).

CONCLUSIONS: The 5-year survival rate in stage I, II, IIIA, and IV lung cancer with operable hematogenous brain metastases corresponds to that in the customary stage IIIA (23%). The disease-free interval exhibited no significant impact on the survival rate. The complaint-free status exhibits a significantly greater impact on the survival rate in hematogenic metastasis.




This article has been cited by other articles:


Home page
 Interact CardioVasc Thorac SurgHome page
D. Kawano, S. Takeo, M. Katsura, S. Tsukamoto, E. Masuyama, and Y. Nakaji
Surgical treatment of stage IV non-small cell lung cancer
Interact CardioVasc Thorac Surg, February 1, 2012; 14(2): 167 - 170.
[Abstract] [Full Text] [PDF]

Home page
 Interact CardioVasc Thorac SurgHome page
A. Modi, H. A. Vohra, and D. F. Weeden
Does surgery for primary non-small cell lung cancer and cerebral metastasis have any impact on survival?
Interact CardioVasc Thorac Surg, April 1, 2009; 8(4): 467 - 473.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Chem.Home page
L. Xi, D. G. Nicastri, T. El-Hefnawy, S. J. Hughes, J. D. Luketich, and T. E. Godfrey
Optimal Markers for Real-Time Quantitative Reverse Transcription PCR Detection of Circulating Tumor Cells from Melanoma, Breast, Colon, Esophageal, Head and Neck, and Lung Cancers
Clin. Chem., July 1, 2007; 53(7): 1206 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Thorac. Surg.Home page
T. M. De Pas, F. de Braud, G. Catalano, C. Putzu, G. Veronesi, F. Leo, P. G. Solli, D. Brambilla, G. Paganelli, and L. Spaggiari
Oligometastatic Non-Small Cell Lung Cancer: A Multidisciplinary Approach in the Positron Emission Tomographic Scan Era
Ann. Thorac. Surg., January 1, 2007; 83(1): 231 - 234.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
ANN THORAC SURG ASIAN CARDIOVASC THORAC ANN EUR J CARDIOTHORAC SURG
J THORAC CARDIOVASC SURG ICVTS ALL CTSNet JOURNALS
Copyright © 2005 by The Society of Thoracic Surgeons.